120 results about "Cell replacement" patented technology

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.

In a pattern correction method, design layout data of a pattern designed by an automated layout unit is entered. An environmental profile is determined based on whether or not another graphics pattern exists at the surroundings of each correction target cell included in the entered design layout data. A target cell name is replaced with a prescribed cell name of correction pattern corresponding to the determined environmental profile by referencing a cell replacement table. An OPC correction pattern corresponding to the replaced cell name is imported from a cell library.

The present invention relates to utrons, RNA molecules which contain promoter regulatory motif(s) and DNA analogs thereof and DNA molecules that can be transcribed to produce the foregoing. In particular, the invention provides gene promoter suppressing nucleic acids which suppress transcription from a promoter of interest. In a preferred embodiment, the invention provides the TSU gene, nucleotide sequences of the TSU gene and RNA, as well as fragments, homologs and derivatives thereof. Methods of isolating TSU genes are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are also provided. In particular, the invention relates to methods for cell replacement therapy, gene therapy or organ transplantation wherein TSU nucleic acids suppress MHC class I and II gene expression, thus preventing immuno-rejection of non-autologous cells or organs. The invention also provides methods for treatment of diseases or disorders by suppression of MHC class I, MHC class II, ICAM-1, B7-1, B7-2, and / or Fc gamma R expression by provision of TSU function.

The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.

The present invention is directed to methods for altering the fate of a cell, tissue or organ type by altering Notch pathway function in the cell. The invention is further directed to methods for altering the fate of a cell, tissue or organ type by simultaneously changing the activation state of the Notch pathway and one or more cell fate control gene pathways. The invention can be utilized for cells of any differentiation state. The resulting cells may be expanded and used in cell replacement therapy to repopulate lost cell populations and help in the regeneration of diseased and / or injured tissues. The resulting cell populations can also be made recombinant and used for gene therapy or as tissue / organ models for research. The invention is directed to methods for of treating macular degeneration comprising altering Notch pathway function in retinal pigment epithelium cells or retinal neuroepithelium or both tissues. The present invention is also directed to kits utilizing the methods of the invention to generate cells, tissues or organs of altered fates. The invention also provides methods for screening for agonists or antagonists of Notch or cell fate control gene pathway functions.

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.

An objective of the present invention is to overcome a problem that there is an inverse relationship between the decellularization rate and the strength of tissue. This problem was solved by immersing tissue in a solution containing a non-micellar amphipathic molecule (e.g., a 1,2-epoxide polymer). Thus, the present invention provides decellularized tissue, in which the cell survival rate of the tissue is less than a level at which calcification or an immune reaction is elicited in an organism and the tissue damage rate of the tissue is suppressed to a level which permits clinical applications. Tissue prepared by the above-described treatment preferably retains a certain level of tissue strength. Further, the tissue of the present invention has an effect of performing cell replacement.

The present invention relates to methods of using granulocyte colony stimulating factor (G-CSF) polypeptide, alone and in conjunction with stromal cell derived factor (SDF-1) polypeptide, to increase the mobilization of c-Kit+ stem cells in the blood, bone marrow, tissue, heart or other organs for the subsequent production of embryoid body-like cell clusters. These embryoid body-like cell clusters can be used for cell replacement therapy, for the treatment of cardiac myopathy and other diseases and disorders, and for screening agents that drive or inhibit differentiation and proliferation.

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as dopaminergic neurons and serotonergic neurons from pluripotent stem cells, for example human embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of cells positive for tyrosine hydroxylase, a specific marker for dopaminergic neurons, have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurological disorders such as Parkinson's disease.

The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy.

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.

The embodiment of the invention provides a cell replacement method and a cell replacement device. The method comprises the following steps of: determining a target cell for cell replacement as a micro cell, wherein the cell replacement comprises cell reselection or cell handover; determining the mobile state or mobile speed of UE (user equipment); and carrying out cell replacement judgment aiming at the target cell according to the moving state or the moving speed of the UE. According to the embodiment of the invention, during the process of carrying out the cell replacement judgment aiming at the micro cell, the moving state or the moving speed of the UE is considered so as to reduce unnecessary cell replacement aiming at the micro cell, thus the system burden and the UE power consumption which are caused by frequent cell replacement are lowered.

The invention provides pluripotent cells modified to overexpress Pdx1 and Ngn3. Pluripotent cells include embryonic stem cells and induced pluripotent stem cells. Methods of producing pancreatic endocrine progenitor cells from ES cells or from iPS cells by forced expression of Pdx1 and Ngn3 are provided. Pancreatic endocrine progenitor cells are useful for drug discovery and cell replacement therapy.

It is necessary to periodically replace a cell of an implantable-type cardiac pacemaker device, which causes suffering to a patient as often as a cell is replaced. Thus, it is an object of the present invention to dispense with cell replacement of the cardiac pacemaker device. A cardiac pacemaker device of the present invention has an antenna and a battery built-in, and an electric power is transmitted to the built-in antenna from outside a body by an electromagnetic wave to store the electric power in the battery. With the use of the electric power stored in the battery, a main body of the pacemaker device can operate. If necessary, the electric power can be supplied wirelessly from outside and a surgery for exchanging a cell becomes unnecessary; therefore, a patient's suffering can be relieved.

Method of differentiating ex vivo expanded stem cells in-tissue anti in vivo are provided. Also provided are method of treating individuals suffering from a disorder necessitating cell replacement or tissue replacement therapy using ex vivo expanded stem cells.

In a pattern correction method, design layout data of a pattern designed by an automated layout unit is entered. An environmental profile is determined based on whether or not another graphics pattern exists at the surroundings of each correction target cell included in the entered design layout data. A target cell name is replaced with a prescribed cell name of correction pattern corresponding to the determined environmental by referencing a cell replacement table. An OPC correction pattern corresponding to the replaced cell name is imported from a cell library.

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as dopaminergic neurons and serotonergic neurons from pluripotent stem cells, for example human embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of cells positive for tyrosine hydroxylase, a specific marker for dopaminergic neurons, have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurological disorders such as Parkinson's disease.

The present invention is directed to methods for readily propagating somatic hair follicle stem cells or melanocyte stem cells. The methods comprise enhancing guanine nucleotide (GNP) biosynthesis, thereby expanding guanine nucleotide pools. This in turn conditionally suppresses asymmetric cell kinetics in the explanted cells. The methods of the invention include pharmacological methods and genetic methods. For example, the resulting cultured somatic hair follicle stem cells can be used for a variety of applications including cell replacement therapies such as hair transplants, gene therapies, and tissue engineering applications, such as the generation of artificial skin and skin regeneration strategies including skin grafts.

The invention discloses a method for configuring a wireless network. According to the method, private network cells are set in an express way region, and the private network cells are covered by a dedicated frequency point region; a neighbouring region relationship is configured for the private network cells and public network cells in the site region of an express way; the neighbouring region relationship between the private network cells and the public network cells is not configured in an express way region without an intersection. According to the method, the defects of frequent cell replacement, low access success rate and conversation quality declining of high-speed mobile terminal equipment in the existing network are solved. By virtue of the method, the replacement frequency of the equipment among the different cells can be reduced, the switching and reselection paths of the equipment in case of high-speed movement are ensured well, and the communication quality is improved. The applications of a radio resource management algorithm, a switching and reselection policy and network parameter values dedicated to high-speed scenes are promoted, thus the quality of the whole network is improved better.

The invention relates to a recombinant adenovirus vector for efficiently inducing a pluripotent stem cell (PS cell) and method for inducing the PS cell by using the recombinant adenovirus vector. The recombinant adenovirus vector is characterized in that the fiber genes therein are B subgroup adenovirus fiber genes, and an Sox2 gene expression cassette and an Oct4 gene expression cassette are connected within the recombinant adenovirus vector in an operating way. The terminally differentiated cell or the adult stem cell of the mammal, particularly the human is infected in vitro, the Oct4 genes and the Sox2 genes are expressed in an ectopic way, and the terminally differentiated cell or the adult stem cell of the mammal, particularly the human can be induced into the PS cell efficiently and rapidly under the synergistic effect of adjusting the epigenetic-inheritance small-molecular medicament. The PS cell of the human can be used for the cell replacement therapy to treat diseases, and the PS cell of the mammal can be used for preparing the transgenic animal model and the animal disease model.

Provided is a composition for treating nerve damage-related diseases. The composition includes a human umbilical cord blood-derived mesenchymal stem cell as an active ingredient. The mesenchymal stem cell isolated and incubated from the human umbilical cord blood migrates to an injured area to be differentiated into a nerve cell or a neuroglial cell at the time of in vivo transplantation. Thus, the mesenchymal stem cell and a composition including the same can be effectively used in cell replacement therapy and gene therapy for treating diseases caused by nerve damage including a stroke, Parkinson's disease, Alzheimer's disease, Pick's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic central nervous system disease and a spinal cord injury.

he present invention is of a method of dynamically generating human embryoid bodies which can be used for generating lineage specific cells and cell lines. Specifically, the present invention can be used to generate ESC-differentiated cells for cell-replacement therapy.

A battery pack having a function for preventing operation of the battery pack when an abnormal replacement of a battery cell is detected or preventing a use of the battery pack in which a cap has been removed. The battery pack generates an encryption code and writes the encryption code to data flash when a battery cell is normally discharged according to a first voltage, and if an abnormal power-on reset is detected on the battery cell, the battery pack may check the stored encryption code to a second encryption code generated upon power-on reset. If the codes do not match, firmware of the battery pack is deleted and / or a fuse is blown, making it is possible to prevent the battery pack from being re-used when the battery cell has been replaced or in which a cap has been removed.

The invention discloses an electric vehicle energy supplying method. The method comprises the following steps: a, detecting an electric vehicle model to be supplied by a model detection system to acquire model information; b, selecting a vehicle positioning program corresponding to the model information from a plurality of pre-saved vehicle positioning programs by a control system according to the detected model information, and controlling the vehicle positioning system for vehicle positioning by the vehicle positioning program; and c, controlling a dynamic cell replacing system by the control system to select a dynamic cell with dynamic cell type information matched with the model information for dynamic cell replacement. The invention also discloses an electric vehicle energy supply system. The method and the system can realize energy supply for various different types of electric vehicles only by a replacement platform.

The invention discloses a wireless sensor network (WSN) node self-powered system based on solar energy-wind energy complementation. The system mainly comprises a solar energy acquisition module, a piezoelectric type vertical axis wind energy acquisition module, a super-capacitor energy storage module and an interface circuit, wherein the solar energy acquisition module acquires luminous energy in the environment through a solar cell panel, the piezoelectric type vertical axis wind energy acquisition module acquires wind energy in the environment, the super-capacitor energy storage module stores the acquired energy into a super capacitor, and the interface circuit provides a channel for energy storage and WSN node power supply. In addition, in order to improve acquisition efficiency of the wind energy acquisition module and reduce influences of a wind direction, a vertical axis piezoelectric type scheme is adopted by the wind energy acquisition module. Due to the facts that rechargeable times of a lithium cell are limited, and in the process of acquisition of environmental energy, charging and discharging are frequent, the super capacitor in the system is used for replacing the lithium cell to serve as a system energy storage unit, and the service life of the energy storage unit can be prolonged. The WSN node self-powered system can collect energy in the environment, does not need to conduct maintenance on a cell, such as cell replacement and charging, therefore prolongs service life of a node, and solves the energy supply problem of a WSN.

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as GABAergic neurons from pluripotent stem cells, for example embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of GABAergic neurons have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurodegenerative disorders and neuronal diseases such as stroke, ischemia, epilepsy, and Huntington's disease.

Method and system for providing a computer implemented process of performing design for testability analysis and synthesis in an integrated circuit design includes partitioning each logic block in an integrated circuit design based on one or more boundaries of multi-cycle initial setup sequence, excluding one or more partitioned logic blocks with multi-cycle initial setup sequence from valid candidate blocks, selecting a constraint setting set, extracting a subset of constraint settings from the selected constraint setting set, applying the extracted subset of constraint settings to the integrated circuit design, performing design for testability analysis and synthesis on the valid candidate blocks, performing scan cell replacement. The scan cell replacement may include performing class selection from a cell library and a gate-level netlist based on affinity between cells, determining a target characterization, such as timing, power, area, for example, for the scan cell replacement, and replacing one or more cells with a corresponding one or more scan cells having the closest target characteristics.

A method of replacing standard cells with high speed cells in the design of a circuit using a computer program, said application specific integrated circuit design comprising a plurality of high speed cells and a plurality of standard cells, said high speed cells and standard cells being arranged to form a plurality of paths on said application specific integrated circuit, said method comprising the steps of: timing said plurality of paths identifying cells occurring on paths for which timing targets are not met; upgrading at least one of said identified cells to a high speed cell.

The invention relates to the unmanned plane electric power inspection field and particularly relates to an automatic unmanned plane cell replacement device for electric power inspection and a control method thereof. The device comprises a cell chamber arranged at a bottom portion of an unmanned plane, undercarriages arranged at two sides of the cell chamber and a cell seat used for replacing the unmanned plane cell. The automatic unmanned plane cell replacement device is advantaged in that automatic cell replacement in an unmanned plane inspection process can be realized, the charging time in the unmanned plane inspection process can be saved, a conductive slot is internally arranged in the unmanned plane, cell replacement without power failure can be realized, and a problem of data or program loss during start of the unmanned plane after power failure can be avoided. The invention further provides a control method based on the automatic unmanned plane cell replacement device, and the method is applied to automatic control on the automatic unmanned plane cell replacement device.

A layout method is provided, adaptable to place cell on a chip. Firstly, a chip area is assigned for a floor plan. A global reservation deployment process is then performed to define a plurality of room units to be uniformly distributed on the chip area. Cells are placed on the chip based on the floor plan. The chip area is categorized into at least a high frequency region and a low frequency region according to operation frequencies of the placed cells thereon. A frequency based reservation deployment process is then performed to move one or more room units distributed in the low frequency region toward the high frequency region. A local cell replacement process, a routing and timing analysis are performed. If hotspots are induced, room units around the hotspots are redistributed, and then the steps of local cell replacement, routing and timing analysis are repeated.